RetinalGeniX Technologies Inc. Appoints Dessy Boneva, MD, FACS to the Board of Directors
December 04, 2023 14:45 ET
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC. APPOINTS
DESSY BONEVA, MD, FACS TO THE BOARD OF DIRECTORS Dr. Boneva is an experienced surgeon skilled in trauma, surgical
RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO
December 01, 2023 12:32 ET
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC. ANNOUNCES HIRING OF INTERIM CFO
Virender Ahluwalia will serve as Interim Chief Financial Officer
Update on the receivership proceedings: submission of a takeover offer to the court-appointed administrators
November 20, 2023 11:45 ET
|
Pixium Vision
Update on the receivership proceedings: submission of a takeover offer to the court-appointed administrators Paris, France, November 20, 2023 – 5:45 pm (CET) – Pixium Vision SA (Euronext Growth...
Point sur la procédure de redressement judiciaire : dépôt d’une offre de reprise auprès des Administrateurs Judiciaires
November 20, 2023 11:45 ET
|
Pixium Vision
Point sur la procédure de redressement judiciaire : dépôt d’une offre de reprise auprès des Administrateurs Judiciaires Paris, France, 20 novembre 2023 - 17h45 CET - Pixium Vision SA (Euronext...
Latest Top500 List Highlights Several World's Fastest and Most Efficient Supercomputers Powered by AMD
November 14, 2023 09:00 ET
|
Advanced Micro Devices, Inc.
SANTA CLARA, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Today, AMD (NASDAQ: AMD) showcased its continued leadership in high performance computing (HPC) at Supercomputing 23. AMD EPYC™ processors and...
Pixium Vision announces the 48-Month Trial Results in Severe Atrophic AMD
November 14, 2023 01:00 ET
|
Pixium Vision
Pixium Vision announces the 48-Month Trial Results in Severe Atrophic AMD Study confirms subretinal prothesis feasible and well-tolerated with no reduction of natural peripheral vision, confirming...
Pixium Vision annonce les résultats de l'essai à 48 mois sur la DMLA atrophique sévère
November 14, 2023 01:00 ET
|
Pixium Vision
Pixium Vision annonce les résultats de l'essai à 48 mois sur la DMLA atrophique sévère L'étude vient confirmer les résultats à 36 mois : l’utilisation de la prothèse sous-rétinienne est possible,...
RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For Investigational Therapeutic Drugs
November 09, 2023 12:58 ET
|
RetinalGeniX Technologies, Inc.
RetinalGeniX Announces Therapeutic Solutions Being Developed for Dry Age-Related Macular Degeneration
and Alzheimer’s Syndrome.
RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam™ Image Visualization Device
November 08, 2023 05:45 ET
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC and AVANIA CRO CONTRACT to GUIDE the DEVELOPMENT of TWO DRUG THERAPIES and the RETINALCAM™ IMAGE VISUALIZATION DEVICE
AMD Reports Third Quarter 2023 Financial Results
October 31, 2023 16:15 ET
|
Advanced Micro Devices, Inc.
SANTA CLARA, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- AMD (NASDAQ:AMD) today announced revenue for the third quarter of 2023 of $5.8 billion, gross margin of 47%, operating income of $224 million,...